Get started
Author

Francesca Crupi

Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis
2022 · Benedetta Sordi, Fiorenza Vanderwert, et al. · Journal of Allergy and Clinical Immunology · 51
Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia
2023 · Francesco Mannelli, Matteo Piccini, et al. · Haematologica · 6
PDF
Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial
2025 · Alessandro Vannucchi, Francesco Mannelli, et al. · Blood · 5
Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis
2025 · Francesca Crupi, Jessica Caroprese, et al. · Frontiers in Allergy · 2
PDF
Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML
2025 · Francesco Mannelli, Matteo Piccini, et al. · Blood Cancer Journal · 2
Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report
2024 · Gaia Ciolli, Andrea Pasquini, et al. · Therapeutic Advances in Hematology · 2
APL-like Subset within NPM1-Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications
2023 · Francesca Crupi, Gaia Ciolli, et al. · Blood · 2
PDF
ALL-256 Nelarabine, Etoposide, and Cyclophosphamide for Adult T Cell Acute Lymphoblastic Leukemia/lymphoma Relapsing After Pediatric-Inspired Frontline Approaches: Report of 3 Cases From a Real-Life Setting
2023 · Andrea Pasquini, Gaia Ciolli, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
PDF
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
2023 · Francesco Mannelli, Francesca Crupi, et al. · Therapeutic Advances in Hematology · 2
PDF
Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management
2022 · Francesca Crupi, Benedetta Sordi, et al. · International Journal of Molecular Sciences · 2
PDF
Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms
2021 · Fiorenza Irushani Vanderwert, Benedetta Sordi, et al. · Blood · 2
Venetoclax and gilteritinib combination for FLT3-mutated relapsed/refractory acute myeloid leukemia: a real-world single-center experience
2026 · Francesca Crupi, Gaia Ciolli, et al. · Haematologica · 1
PDF
APL‐like subset within NPM1 ‐mutated AML: A distinct immunophenotype correlating with early vascular complications
2026 · Francesco Mannelli, Francesca Crupi, et al. · HemaSphere · 1
B07 | Molecular risk profiling in myeloproliferative neoplasms blast phase treated with venetoclax and decitabine: a three-gene score for survival prediction
2026 · Francesca Crupi · Haematologica · 1
PDF
Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine
2025 · Paola Guglielmelli, Francesca Crupi, et al. · Blood · 1
PDF
AML-558: Low Rate of Fungal Infections in a Population of Elderly/Unfit AML Patients Receiving Azacitidine and Venetoclax Without Posaconazole Prophylaxis: A Monocentric Experience
2025 · Matteo Piccini, Giorgio Cannetti, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
AML-555: MYC-Rearranged Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report
2025 · Giorgio Cannetti, Barbara Scappini, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis
2024 · Mariarita Sciumè, Fabio Serpenti, et al. · Hematological Oncology · 1
Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy
2023 · A. Atanasio, A. Vanni, et al. · Leukemia Research · 1
PDF
Clofarabine and intermediate-dose cytarabine after venetoclax failure in relapsed/refractory acute myeloid leukemia: a retrospective single-center experience
2026 · Gaia Ciolli, Matteo Piccini, et al. · Research Square
PDF
Clinical Experience With Venetoclax‐Based Combinations for Relapsed/Refractory or MRD ‐Positive NPM1 ‐Mutated Acute Myeloid Leukemia
2026 · Matteo Piccini, Naseema Gangat, et al. · American Journal of Hematology
PDF
Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance
2025 · Francesco Mannelli, Giacomo Gianfaldoni, et al. · Blood
PDF
POSTER: AML-558 Low Rate of Fungal Infections in a Population of Elderly/Unfit AML Patients Receiving Azacitidine and Venetoclax Without Posaconazole Prophylaxis: A Monocentric Experience
2025 · Matteo Piccini, Giorgio Cannetti, et al. · Clinical Lymphoma Myeloma & Leukemia
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting
2024 · Gaia Ciolli, Matteo Piccini, et al. · Haematologica
PDF
Author response for "Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis"
2024 · Mariarita Sciumè, Fabio Serpenti, et al.
Works count: 38
Citation count: 86
H-index: 3
I10-index: 1
Year
Topic
Type